Capricor Therapeutics (NASDAQ:CAPR) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

Capricor Therapeutics Inc (NASDAQ:CAPR) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $12.95 and traded as high as $19.30. Capricor Therapeutics shares last traded at $18.45, with a volume of 652,168 shares.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CAPR. Cantor Fitzgerald reissued an “overweight” rating and set a $8.00 target price on shares of Capricor Therapeutics in a research note on Friday, September 20th. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. Maxim Group lifted their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Oppenheimer reissued an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Finally, Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 target price for the company. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.67.

Capricor Therapeutics Stock Down 0.8 %

The stock has a market capitalization of $837.74 million, a P/E ratio of -19.84 and a beta of 4.00. The firm’s 50 day simple moving average is $12.95 and its two-hundred day simple moving average is $7.75.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The business had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. As a group, equities research analysts expect that Capricor Therapeutics Inc will post -1.17 earnings per share for the current year.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was bought at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 12.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in Capricor Therapeutics during the first quarter worth about $40,000. Main Street Financial Solutions LLC boosted its holdings in Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the last quarter. SG Americas Securities LLC purchased a new position in Capricor Therapeutics during the third quarter worth about $133,000. Bank of New York Mellon Corp boosted its holdings in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares during the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in Capricor Therapeutics by 25.2% during the third quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock worth $1,040,000 after purchasing an additional 13,762 shares during the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.